ISR

ISORAY
AMEX

Real-time Quotes | Nasdaq Last Sale

0.6405
+0.0678
+11.84%
After Hours: 0.6300 -0.0105 -1.64% 19:55 07/07 EDT
OPEN
0.5800
PREV CLOSE
0.5727
HIGH
0.6700
LOW
0.5610
VOLUME
1.24M
TURNOVER
--
52 WEEK HIGH
1.060
52 WEEK LOW
0.2875
MARKET CAP
43.33M
P/E (TTM)
-12.8357
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ISR stock price target is 1.500 with a high estimate of 1.750 and a low estimate of 1.250.

EPS

ISR News

More
Edited Transcript of ISR.A earnings conference call or presentation 12-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 06/20 00:06
Isoray and University of Cincinnati Physicians Company Sign Research Agreement to Study Treatment of Head and Neck Cancers
GlobeNewswire · 06/17 13:13
Isoray, University Of Cincinnati Physicians Company Sign Research Agreement To Study Treatment Of Head, Neck Cancers
Benzinga · 06/17 12:15
IsoRay (ISR) Upgraded to Buy: What Does It Mean for the Stock?
Zacks · 06/04 17:00
Shares Of Isoray Tick Higher After Company Announces Second Ten Year Data On Efficacy Of Cesium-131 Internal Radiation Therapy To Treat Prostate Cancer
Benzinga · 06/02 12:14
Second Ten Year Data Report Demonstrates Efficacy of Isoray's Cesium-131 Internal Radiation Therapy in the Treatment of Prostate Cancer
RICHLAND, Wash., June 02, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR) today announced that the results of a new ten year study show positive outcomes for low-risk and intermediate-risk prostate cancer
Benzinga · 06/02 12:13
Second Ten Year Data Report Demonstrates Efficacy of Isoray’s Cesium-131 Internal Radiation Therapy in the Treatment of Prostate Cancer
Isoray, Inc. (NYSE American: ISR) today announced that the results of a new ten year study show positive outcomes for low-risk and intermediate-risk prostate cancer patients treated with Isoray’s Cesium-131 (Cesium Blu) internal radiation therapy (brachytherap
GlobeNewswire · 06/02 12:13
Company News for May 14, 2020
Zacks · 05/14 14:50

Industry

Biotechnology & Medical Research
+1.75%
Pharmaceuticals & Medical Research
-0.01%

Hot Stocks

Symbol
Price
%Change

About ISR

IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device.
More

Webull offers kinds of IsoRay, Inc. stock information, including AMEX:ISR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ISR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ISR stock methods without spending real money on the virtual paper trading platform.